Treatment of Advanced Systemic Mastocytosis with Midostaurin: Practical Guidance for Optimal Therapy and Management

Systemic mastocytosis (SM) is a rare disease with a range of clinical presentations, and the vast majority of patients have a KIT D816V mutation that results in a gain of function. The multikinase/KIT inhibitor midostaurin inhibits the D816V mutant and has a well-established role in treating advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Papayannidis, Cristina, Federico, Vincenzo, Fianchi, Luana, Pregno, Patrizia, Pugliese, Novella, Romano, Alessandra, Grifoni, Federica Irene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652003/
https://www.ncbi.nlm.nih.gov/pubmed/36425146
http://dx.doi.org/10.4084/MJHID.2022.073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652003/
https://www.ncbi.nlm.nih.gov/pubmed/36425146
http://dx.doi.org/10.4084/MJHID.2022.073

Ejemplares similares